The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Abstract
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation agents engage not only GLP-1 receptors but also those for other gastro-entero-pancreatic hormones such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY to enhance energy uptake, storage, and expenditure through synergistic mechanisms. Both GIP receptor agonism and antagonism, particularly in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide, combining GLP-1 receptor agonism with GIP receptor antagonism, exemplifies this innovative approach. Glucagon coagonists like survodutide and mazdutide have demonstrated significant weight loss and improved glycemic control. Amylin-based agents, including CagriSema (cagrilintide + semaglutide) and amycretin, enhance satiety and glycemic outcomes through complementary actions. Further innovation is seen in triple agonists such as retatrutide, which targets GIP, GLP-1, and glucagon receptors to amplify metabolic effects. Meanwhile, the emergence of orally active small-molecule GLP-1 receptor agonists like danuglipron and orforglipron, which are resistant to enzymatic degradation, marks a major advance in patient-friendly drug delivery. This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents, excluding already approved drugs like liraglutide, semaglutide, and tirzepatide. We highlight how multireceptor agonists and oral GLP-1-based therapies may reshape the future landscape of obesity and type 2 diabetes treatment by offering more effective and better-tolerated options.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
Cited work 10.3831/kpi.2017.20.029 · retracted 2020-03-31 · notice 10.3831/kpi.2020.23.007 · this paper published 2025-10-07
Citations
Cites
1 retracted
A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus.
Gizaw, M., Anandakumar, P., & Tolessa, D. (2017) · Europe PMC (PubMed Central) · doi:10.3831/kpi.2017.20.029 · Cited by 68
RetractedLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
(2020) · PubMed · Cited by 2,642
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Cited by
Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies
Alhazmi, A., & le Roux, C. W. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1788698 · Cited by 10
Self-citationLempesis, I. G., & Dalamaga, Μ. (2026) · Metabolism Open · doi:10.1016/j.metop.2026.100463 · Cited by 8
“Multi-receptor agonists combining GLP-1 with glucose-dependent insulinotropic polypeptide (GIP), glucagon, or amylin demonstrate enhanced weight loss and metabolic benefits through synergistic mechanisms that augment energy expenditure, lipolysis, and satiety beyond GLP-1 alone [39].”
The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population
Accacha, S. D., Barillas, J., Gabriel, L., Srivastava, A., Gulkarov, S., Apsan, J., Leon, J. D., & Reiss, A. B. (2026) · Biomedicines · doi:10.3390/biomedicines14010198 · Cited by 4
“Their use can be an effective strategy in improving overall glycemic control [208–210].”
Current Knowledge of Obesity‐Related Vascular Injury
Liu, J., & Yang, D. (2025) · Obesity Reviews · doi:10.1111/obr.70080 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Metadata
- Authors
- Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S.
- Affiliations
- The Catholic University of Korea Bucheon St. Mary's Hospital (KR)
- University College Dublin (IE)
- Helmholtz Munich (DE)
- St. Josef-Hospital (DE)
- Seoul National University (KR)
- Corresponding author
- Nauck, Michael A
- Lim, Soo
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2025-10-07
- Volume
- 47
- Issue
- 2
- Pages
- 159-177
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W4414917129
- Semantic Scholar
- d9402dc1978bdb4910ddb479ab4625eee7177431
- Cited by
- 40
- References
- 209
- Citations by year
- 2026: 36 · 2025: 4
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, obesity, glucagon receptor agonist, amylin receptor agonist, peptide YY, survodutide, mazdutide, cagrilintide, retatrutide, orforglipron, oral GLP-1 receptor agonists, weight loss, glycemic control
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Obesity, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. https://app.cochat.ai/papers/10.1210/endrev/bnaf036
- The paper
- Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026). Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocrine Reviews. https://doi.org/10.1210/endrev/bnaf036
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.